Movement Alert｜Hansoh Pharmaceutical Rises 4.88% in Regular Trading, Pharma Sector Rally Combines with Dense Pipeline Catalysts

Market Focus06-29

On June 29, Hansoh Pharmaceutical rose 4.88% in regular trading, trading at HK$30.06/share, with turnover of HK$125 million. The move was driven by broad pharmaceutical sector strength and a concentrated release of company-specific catalysts.

On the sector front, pharmaceutical stocks rallied collectively, with CSPC Pharma up 9.27%, Asymchem up 8.72%, and Sino Biopharmaceutical up 6.81%. At the company level, multiple catalysts converged: on June 25, Hansoh's targeted ADC drug application was accepted by CDE with potential deal value exceeding US$1.5 billion; on June 26, shareholders approved a buyback authorization of up to 10% of issued shares. Earlier, both the HS-10568 injection for secondary hyperparathyroidism in chronic kidney disease patients and the GLP-1/GIP dual-receptor agonist olatorepatide injection for weight management had their NDA applications accepted by NMPA, accelerating the commercialization timeline of the innovative pipeline. CMBI recently reiterated its Buy rating, citing a renewed bottom-fishing opportunity in the pharmaceutical industry.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1176060253?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-29 10:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176060253","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Hansoh Pharmaceutical Rises 4.88% in Regular Trading, Pharma Sector Rally Combines with Dense Pipeline Catalysts","media":"Market Focus","content":"<p><p>On June 29, Hansoh Pharmaceutical rose 4.88% in regular trading, trading at HK$30.06/share, with turnover of HK$125 million. The move was driven by broad pharmaceutical sector strength and a concentrated release of company-specific catalysts.</p><p>On the sector front, pharmaceutical stocks rallied collectively, with CSPC Pharma up 9.27%, Asymchem up 8.72%, and Sino Biopharmaceutical up 6.81%. At the company level, multiple catalysts converged: on June 25, Hansoh's targeted ADC drug application was accepted by CDE with potential deal value exceeding US$1.5 billion; on June 26, shareholders approved a buyback authorization of up to 10% of issued shares. Earlier, both the HS-10568 injection for secondary hyperparathyroidism in chronic kidney disease patients and the GLP-1/GIP dual-receptor agonist olatorepatide injection for weight management had their NDA applications accepted by NMPA, accelerating the commercialization timeline of the innovative pipeline. CMBI recently reiterated its Buy rating, citing a renewed bottom-fishing opportunity in the pharmaceutical industry.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Hansoh Pharmaceutical Rises 4.88% in Regular Trading, Pharma Sector Rally Combines with Dense Pipeline Catalysts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Hansoh Pharmaceutical Rises 4.88% in Regular Trading, Pharma Sector Rally Combines with Dense Pipeline Catalysts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-29 10:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 29, Hansoh Pharmaceutical rose 4.88% in regular trading, trading at HK$30.06/share, with turnover of HK$125 million. The move was driven by broad pharmaceutical sector strength and a concentrated release of company-specific catalysts.</p><p>On the sector front, pharmaceutical stocks rallied collectively, with CSPC Pharma up 9.27%, Asymchem up 8.72%, and Sino Biopharmaceutical up 6.81%. At the company level, multiple catalysts converged: on June 25, Hansoh's targeted ADC drug application was accepted by CDE with potential deal value exceeding US$1.5 billion; on June 26, shareholders approved a buyback authorization of up to 10% of issued shares. Earlier, both the HS-10568 injection for secondary hyperparathyroidism in chronic kidney disease patients and the GLP-1/GIP dual-receptor agonist olatorepatide injection for weight management had their NDA applications accepted by NMPA, accelerating the commercialization timeline of the innovative pipeline. CMBI recently reiterated its Buy rating, citing a renewed bottom-fishing opportunity in the pharmaceutical industry.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1176060253","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176060253","pubTimestamp":1782701290,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 29, Hansoh Pharmaceutical rose 4.88% in regular trading, trading at HK$30.06/share, with turnover of HK$125 million. The move was driven by broad pharmaceutical sector strength and a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"异动快讯|翰森制药常规盘涨4.88%医药板块涨势叠加密集管线催化剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"On June 29, Hansoh Pharmaceutical rose 4.88% in regular trading, trading at HK$30.06/share, with turnover of HK$125 million. The move was driven by broad pharmaceutical sector strength and a concentrated release of company-specific catalysts.On the sector front, pharmaceutical stocks rallied collectively, with CSPC Pharma up 9.27%, Asymchem up 8.72%, and Sino Biopharmaceutical up 6.81%. At the company level, multiple catalysts converged: on June 25, Hansoh's targeted ADC drug application was accepted by CDE with potential deal value exceeding US$1.5 billion; on June 26, shareholders approved a buyback authorization of up to 10% of issued shares. Earlier, both the HS-10568 injection for secondary hyperparathyroidism in chronic kidney disease patients and the GLP-1/GIP dual-receptor agonist olatorepatide injection for weight management had their NDA applications accepted by NMPA, accelerating the commercialization timeline of the innovative pipeline. CMBI recently reiterated its Buy rating, citing a renewed bottom-fishing opportunity in the pharmaceutical industry.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1176060253","isCrawlerRequest":true}